Biocon to merge Biocon Biologics in $5.5 billion deal

Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million

Takeda seals $1.2 billion oncology deal with Innovent Biologics

Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent

Denali clinches $275 million royalty deal to power potential breakthrough Hunter Syndrome therapy

Merck Animal Health wins FDA’s fast-track green light for first-in-decades cattle parasite treatment

The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation

Bristol Myers Squibb secures FDA nod for Breyanzi in marginal zone lymphoma

The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population

Lupin receives FDA’s tentative approval for Siponimod tablets

Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis

Medtronic and Symbiosis International inaugurate center for advanced surgical, cadaver-based training

The center will offer training to super-specialist doctors and healthcare professionals in various fields

Granules’ packaging facility in US completes FDA inspection with zero observations

Granules Consumer Health serves as Granules’ front-end division for OTC products in the US

Excelsior Sciences raises $95 million for drug discovery with AI-ready chemistry

Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions

Peapod Bio teams up with Enamine to supercharge drug discovery

Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target